Output Biosciences Analysis: $125K Raised
What is Output Biosciences?
Output Biosciences builds biologically aware generative AI and large biological models. The company says its systems handle long, nonlinear, fragmented, and high-dimensional biological data. It says the technology can generate breakthrough medicines and support disease diagnosis, treatment, and prevention.
Location
New York, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- Drug Discovery, Biological Data Modeling, Systems Biology, Disease Modeling, Pharmaceutical Research, Drug Candidate Generation, Comprehensive Biological Integration, AI-Enabled Biological Tasks
How much Output Biosciences raised
Pre-Seed - $125,000
August 22, 2021Lead Investor: Y Combinator, Able Partners, First Round Capital, Great Oaks Venture Capital
Who are the founders of Output Biosciences
AM
Adi Mashiach
Co-Founder, CEO
MM
Mirella Mashiach
Co-Founder, COO
Market Focus
Output Biosciences primarily focuses on the biotechnology industry, specifically in the development of biologically-aware generative AI to understand complex biological systems and create breakthrough medicines.
Investors
- Y Combinator
- Able Partners
- First Round Capital
- Great Oaks Venture Capital
Competitors Overview
Output Biosciences operates in the biotechnology sector, focusing on biologically-aware generative AI for drug discovery and understanding complex biological systems. Its main competitors include:
-
Insilico Medicine: This company utilizes AI to streamline drug discovery and development processes. Insilico is known for its AI-powered engine that predicts the effectiveness of small molecules and biologics, which allows for faster identification of potential drugs. Their focus on precision medicine and biomarker development gives them a competitive edge in personalized therapies.
-
Cradle: A Dutch startup that employs generative AI to assist biologists in designing improved proteins. Cradle's technology accelerates research and development, making it a strong competitor in the protein design space.
-
Exscientia: This company focuses on AI-driven drug discovery, emphasizing precision medicine. Exscientia's platform integrates AI with human expertise to optimize drug candidates, which enhances the efficiency of the drug development process.
-
Recursion Pharmaceuticals: They combine biology and AI to discover new drugs, focusing on rare diseases. Their unique approach to integrating vast biological data with machine learning sets them apart in the competitive landscape.
-
Generate Biomedicines: Specializing in protein therapeutics, Generate Biomedicines uses AI to design and optimize proteins for therapeutic use, which positions them as a notable competitor in the biologics market.
These companies leverage advanced AI technologies to enhance drug discovery and development, each with unique strengths that differentiate them from Output Biosciences.
Business Model
B2B model leveraging AI for biological insights; revenue from software solutions and partnerships.
See something that needs updating? Suggest edits to this profile.